GSK chief rules out AstraZeneca buyout

GSK ($GSK) chief Andrew Witty (photo) quickly dismissed any idle speculation that he might be interested in buying the struggling British rival AstraZeneca ($AZN). A buyout, he said, would be "very distracting". Some analysts have been wondering if David Brennan's departure at Astra would set the stage for a big merger. But such megadeals are in distinct disfavor right now. Story